Pure Storage vs State Street SPDR S&P Biotech ETF — how do they compare? Pure Storage trades at $154.49 (market cap $50.17B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Pure Storage is far larger — about 5× State Street SPDR S&P Biotech ETF's market cap, and Pure Storage is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pure Storage for 3 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| P | XBI | |
|---|---|---|
Market Cap | $50.17B | $10.11B |
Volume | 5,733,762 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $152.84 | $169.55 |
52-Week Low | $56.99 | $104.99 |
Typical Hold Time | 3 Days | 38 Days |
Enterprise Value | $49.39B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →